Literature DB >> 11992753

Phenotypic spectrum of Salla disease, a free sialic acid storage disorder.

Tarja T Varho1, Liisa E Alajoki, Kristiina M Posti, Tapio T Korhonen, Martin G Renlund, Samuel R G Nyman, Matti L Sillanpää, Pertti P Aula.   

Abstract

Salla disease (MIM 269920) represents the mildest phenotype among recessively inherited lysosomal-free sialic acid storage disorders. Although the vast majority of Salla disease patients in Finland share the same founder mutation, R39C in the SLC17A5 gene, there still is a wide clinical variation among mentally retarded, ataxic patients. We evaluated neurologic and neurocognitive findings of Salla disease in a cross-sectional study of 41 Finnish patients who were 11 months to 63 years of age (median = 19.5 years). The phenotype of Salla disease could be classified into two main categories. The majority of patients (90%) had so-called conventional phenotype, including a subgroup of seven patients with relatively mild symptoms. All but two patients with conventional phenotype were homozygous for the Finnish founder mutation. Four severely disabled, profoundly mentally retarded patients, 15-28 years of age, clearly could be clinically delineated as a separate group, likely reflecting the underlying compound heterozygous genotype. A typical developmental pattern could be outlined in the conventional type of the disease, emphasizing a strong motor handicap in Salla disease. The cognitive profile consisted of better verbal ability, especially speech comprehension, compared with nonverbal functioning in all patients. Our results indicate a partial genotype-phenotype correlation, although factors other than the molecular background are also involved in the phenotypic manifestation of Salla disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992753     DOI: 10.1016/s0887-8994(01)00406-4

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  14 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Functional characterization of wild-type and mutant human sialin.

Authors:  Pierre Morin; Corinne Sagné; Bruno Gasnier
Journal:  EMBO J       Date:  2004-10-28       Impact factor: 11.598

3.  The lysosomal sialic acid transporter sialin is required for normal CNS myelination.

Authors:  Laura M Prolo; Hannes Vogel; Richard J Reimer
Journal:  J Neurosci       Date:  2009-12-09       Impact factor: 6.167

4.  Identification of a vesicular aspartate transporter.

Authors:  Takaaki Miyaji; Noriko Echigo; Miki Hiasa; Shigenori Senoh; Hiroshi Omote; Yoshinori Moriyama
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

Review 5.  Free sialic acid storage disorder: Progress and promise.

Authors:  Marjan Huizing; Mary E Hackbarth; David R Adams; Melissa Wasserstein; Marc C Patterson; Steven U Walkley; William A Gahl
Journal:  Neurosci Lett       Date:  2021-04-20       Impact factor: 3.046

Review 6.  Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.

Authors:  Shreyas Bhat; Ali El-Kasaby; Michael Freissmuth; Sonja Sucic
Journal:  Pharmacol Ther       Date:  2020-12-10       Impact factor: 12.310

Review 7.  Diabetes-Associated Mutations in Proinsulin Provide a "Molecular Rheostat" of Nascent Foldability.

Authors:  Balamurugan Dhayalan; Michael A Weiss
Journal:  Curr Diab Rep       Date:  2022-02-04       Impact factor: 4.810

8.  Hyccin, the molecule mutated in the leukodystrophy hypomyelination and congenital cataract (HCC), is a neuronal protein.

Authors:  Elisabetta Gazzerro; Simona Baldassari; Caterina Giacomini; Veronica Musante; Floriana Fruscione; Veronica La Padula; Roberta Biancheri; Sonia Scarfì; Valeria Prada; Federica Sotgia; Ian D Duncan; Federico Zara; Hauke B Werner; Michael P Lisanti; Lucilla Nobbio; Anna Corradi; Carlo Minetti
Journal:  PLoS One       Date:  2012-03-26       Impact factor: 3.240

9.  Homozygosity for the p.K136E mutation in the SLC17A5 gene as cause of an Italian severe Salla disease.

Authors:  R Biancheri; A Rossi; H A Verbeek; R Schot; F Corsolini; S Assereto; G M S Mancini; F W Verheijen; C Minetti; M Filocamo
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

10.  An Unusual Developmental Profile of Salla Disease in a Patient with the SallaFIN Mutation.

Authors:  Liisa E Paavola; Anne M Remes; Pirkko H Sonninen; Vesa V Kiviniemi; Tapio T Korhonen; Kari Majamaa
Journal:  Case Rep Neurol Med       Date:  2012-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.